Resonance Health Ltd · ASX:RHT
Resonance Health — Investor Presentation (May 2005)
21 slides from Resonance Health's investor presentation, May 31, 2005
Slide 1: Commercialising the FerriScan Technology: Investor Update May 2005
resonance health limited Commercialising the Ferriscan™ Technology “The Future of Liver Diagnosis” — Investor Update | oe May 2005
Slide 2: Resonance Health Limited (ASX:RHT)
Resonance Health Limited (ASX:RHT) | e Resonance Health is a Healthcare service provider p — Key Regulatory clearances for lead product (FerriScan) (US, Europe, Au — Significant strategic alliances established (DCA Group, Novartis), others imminent. — Initial sales of FerriScan achieved. . . — Pipel
Slide 3: What is the FerriScan technology?
What is the FerriScan technology? * Asafe, non-invasive and accurate test to measure liver iro * Utilises existing MRI equipment, proprietary software anda patented iron “marker” known as “R2” * Provides clinicians around the world with a new and safe diagnostic tool to track liver iron levels in th
Slide 4: Why Test for Iron Overload?
Why Test for lron Overload? * Chronic disorders of iron metabolism are among the diseases . : : — Conditions include: heamochromatosis and haemoglobinopathies = — More that 10 million people affected globally * Excess iron accumulates in the body and, if left untreated, is a major cause of organ dam
Slide 5: Distribution Map
Distribution Map ~{lron Overload Disorders Tm | Hemogiohingpathies [A Haemachromatasis 4,000,000 10,000,000 resonance oecith limited
Slide 6: FerriScan Has The Potential To Reduce Cost & Improve Patient Care
FerriScan Has The Potential To Reduce Cost & improve Patient Care Reduced cost. of care ‘Improve patient monitoring and safety Only a liver biopsy provides direct information on possible contributions of iron to the progression of iron overload diseases however, an estimated 60% of patients refuse l
Slide 7: FerriScan service delivery
FerriScan service delivery MRI image transmitted IV's Central Image. Analysis Centre Teal reports *No new equipment purchases required at radiology centre — standard MRI instruments *MRI images processed at RHT Analysis Centre using IVB proprietary software, optimising quality control and security o
Slide 8: FerriScan: Iron overload - USA & Australian Market Potential
FerriScan: lron overload - USA & Australian Market Potential Au Total Market: genetic 125,000 predisposition for iron overload Addressable Market: Clinically 33.000 750 000 significant iron overload . . 1M . Potential FerriScan™ service fee $250 - $350 $250 - $450 (AUD) Add bl ket potential AUD ress
Slide 9: Indicative Model of Potential Gross Profit
indicative Mocel of Potential Gross Profit Based on %US / Aus Test Numbers Addressable Market 20,000 2.5% $6M $3.9M 40,000 5% $12M $7.8M 60,000 7.5% $18M $11.7M 100,000 2 12.5% $30M $19.5M Note: ‘ At average revenue of AUD$300 per test 2 <4 scans / week at 500 MRI sites
Slide 10: FerriScan: Roll-out strategy
FerriScan: Roll-out strategy Primary distribution channel * Diagnostic imaging groups — Australia: DCA Group — UK: MedTel and DCA Group — US: Major US chain(s) (100+ installed MRI sites — largest have 300+) Secondary channels * Service provision to clinical trials — Pharmaceutical companies: e.g. Ex
Slide 11: FerriScan: Roll-out schedule
44 FerriScan: Roll-out schedule Australia Trial marketing commenced (April) Launched to key physicians in WA, SA, Queensland and Ta First sales achieved / referrals made Victoria and NSW currently being activated Expanded roll-out second half 2005 US Imaging company discussions at late stage Trial m
Slide 12: Resonance Health - a global diagnostic service provider with medical device margins
12 Resonance Health - a global diagnostic service provider with medical device margins amuses moe aeAM NILA IVB is uniquely positioned as a Diagnostic/Theranostic Service Medical Devices: European Diagnostic: ; Innogenetics; BioPredictive Australian Device: . Sirtex : USA: MedicSight; Vital Images;
Slide 13: Benchmark examples of Diagnostic imaging companies
13 Benchmark examples of Diagnostic imaging companies resonance oecith limited Company Description Mkt Cap: Cash: MedicSight Medicsight is a medical imaging software company. Its core MC: US$165m (USA) technology is focused on developing automatic detection and Cash: US$8m Nov2008, July 2004, Nav 20
Slide 14: Resonance Health - New Board Members
44 Resonance Health —- New Board Members Mr lan Anderson (48) — Non-Executive Director BBus (ECU) MBA (UWA) Mr Anderson is currently on secondement to the North Metropolitan Area Health Service of Western Australia as Area Executive Director, Finance & Corporate Services. Prior to this, Mr Anderson
Slide 15: Resonance Health - New Board Members
416 Resonance Health —- New Boord Members Dr Jay Ives (49) - Non-Executive Director MB ChB (Otago) FRANZCR Dr Ives is a former partner and member of the Executive Committee of SKG Radiology -” - (prior to its sale to Sonic Healthcare Ltd), and continues in his role as Technical : Director for the pr
Slide 16: Resonance Health - New Board Members
16 Resonance Health —- New Board Members Dr James Williams (35) — Managing Directo BSc (Hons) (Aberdeen) PhD (Melbourne) MBA (UW Dr Williams has a track record of establishing health technology. companies, : academic institutions, and rapid progression of their products to market. Dr-Williams has --
Slide 17: Operational Management
- Glenn Smith, BA/BEcon MBA, Marketing Direct Operational Management — Prior roles include CEO, Tri-Med fesponsibie for ro ing ol over 30 countries so - Marketing leader responsible for establishing an e-commerce, telemedicine pro line generating over $50 million in revenue + Dr Janet Preuss BSc PhD
Slide 18: RHT capital structure
18 RHT capital structure (As at 31 March 2005) Shares on issue: Currently on issue and listed (RHT) ; Proposed issue of ordinary shares to |VB shareholders” : Total shares on issue — all classes 189,494, Market Capitalisation at 30 May 2005 closing ($0.14) _ $26.5 million - Performance Shares 16,000
Slide 19: Resonance Health: Positioned for growth
Resonance Health: Positioned for growth 1 1. Key regulatory clearances achieved (Australia, US an 2. Significant partnerships established (DCA Group, MedTel an Novartis). Others pending. . 3. Initial commercial sales achieved in both Australia and internationally through partners 4. Research program
Slide 20: Forward looking statements and risks
20 Forward looking statements and risks This presentation contains.forward-looking statem management's current expectations. These statements may | from actual future events or results due to the range of risks an uncertainties associated with the healthcare technology product development process in
Slide 21: Contact Details
21 Contact Details Dr James Williams, Managing Director Resonance Health Ltd ABN 96 006 762 492 oo First Floor, 216 Stirling Highway, Claremont Western Australia 6010. Tel +61 8 9286 5300 Fax +61 8 9286 5399 Tony Fitzgerald, Executive Director Resonance Health Ltd ABN 96 006 762 492 Ground Floor, 11